Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat f... Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.005 | -2.17391304348 | 0.23 | 0.24 | 0.225 | 3282794 | 0.23438329 | DE |
| 4 | 0.005 | 2.27272727273 | 0.22 | 0.265 | 0.22 | 8333983 | 0.23946752 | DE |
| 12 | 0.02 | 9.75609756098 | 0.205 | 0.265 | 0.195 | 6662912 | 0.23567146 | DE |
| 26 | 0.015 | 7.14285714286 | 0.21 | 0.265 | 0.195 | 4824159 | 0.22960494 | DE |
| 52 | -0.04 | -15.0943396226 | 0.265 | 0.28 | 0.19 | 4083796 | 0.23091853 | DE |
| 156 | -34.775 | -99.3571428571 | 35 | 35 | 0.19 | 1959802 | 0.30237255 | DE |
| 260 | -34.775 | -99.3571428571 | 35 | 35 | 0.19 | 1180529 | 0.30237255 | DE |
ProfitScout
2分前
WhatMoney?
2分前
peafunke
2分前
Wallstreeter$$$
2分前
CryptoRain
3分前
boston127
3分前
ducci1
3分前
Buckey
3分前
FeMike
5分前
ducci1
5分前
Moneysign5
5分前
boston127
6分前
Lone Clone
6分前
lighter than AIR
7分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。